{"id":"aripiprzole","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["Aripiprazole (Abilify)"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-28T04:54:21.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00567099","phase":"NA","title":"Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole","status":"UNKNOWN","sponsor":"New Mexico VA Healthcare System","startDate":"2003-08","conditions":"Schizophrenia, Sensory Gating","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"AGGRESSION"},{"count":1,"reaction":"AGITATION"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BLOOD CREATINE PHOSPHOKINASE INCREASED"},{"count":1,"reaction":"DELUSION OF GRANDEUR"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"DRUG LEVEL ABOVE THERAPEUTIC"},{"count":1,"reaction":"MOOD SWINGS"},{"count":1,"reaction":"MYOGLOBIN BLOOD INCREASED"},{"count":1,"reaction":"NEUROLEPTIC MALIGNANT SYNDROME"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Aripiprzole","genericName":"Aripiprzole","companyName":"New Mexico VA Healthcare System","companyId":"new-mexico-va-healthcare-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}